Latest Kaiser Health News Stories
The decision in Maryland’s case could slow momentum for other states that are attempting to take action to curb high drug costs.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s “Newsmakers” program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
Happy Friday! Welcome to the inaugural edition of KHN’s Friday Breeze. As the newsletter editor at Kaiser Health News, I read hundreds of health stories a week, and I’m here each Friday to sum up the more important ones — interesting reads, news that will have lasting impact, unique takes on the big problems in the […]
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Sarah Kliff of Vox.com, Anna Edney of Bloomberg News and Alice Ollstein of Talking Points Memo discuss President Donald Trump’s firing of David Shulkin, the secretary of Veterans Affairs, and Shulkin’s claim that he was forced out by those who want to privatize VA health care.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Margot Sanger-Katz of The New York Times discuss the apparent demise of bipartisan legislation aimed at shoring up parts of the Affordable Care Act. They also discuss aggressive new efforts by the Food and Drug Administration to regulate tobacco products. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
Almost three-quarters of Americans think the pharmaceutical industry has too much power in the nation’s capital, according to the Kaiser Family Foundation.
How a prescription wiped out one woman’s health reimbursement account, raising questions about prescription drug price tags and about how health care professionals deal (or don’t) with medical costs.
Last month’s budget deal means Medicare beneficiaries are eligible for physical and occupational therapy indefinitely. Plus, prescription drug costs will fall for more seniors.
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
KHN correspondent Shefali Luthra answered a wide variety of questions about health care in a Reddit “Ask Me Anything” chat.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.